TransMedics Group's (TMDX) Hold Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of TransMedics Group (NASDAQ:TMDX - Free Report) in a report published on Tuesday,Benzinga reports.

Several other brokerages also recently commented on TMDX. Canaccord Genuity Group reissued a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Piper Sandler reiterated an "overweight" rating and set a $145.00 price target (up previously from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Finally, Oppenheimer raised their price objective on TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $127.33.

TransMedics Group Stock Down 0.4%

Shares of NASDAQ:TMDX traded down $0.44 during trading on Tuesday, reaching $123.56. 1,290,484 shares of the stock were exchanged, compared to its average volume of 1,366,035. TransMedics Group has a 1-year low of $55.00 and a 1-year high of $177.37. The stock has a fifty day moving average of $113.37 and a two-hundred day moving average of $83.69. The company has a debt-to-equity ratio of 1.92, a current ratio of 9.10 and a quick ratio of 8.32. The firm has a market cap of $4.18 billion, a price-to-earnings ratio of 90.85 and a beta of 2.10.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.41. The firm had revenue of $143.54 million for the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The business's revenue was up 48.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.35 earnings per share. Research analysts anticipate that TransMedics Group will post 1 earnings per share for the current fiscal year.

Insider Activity at TransMedics Group

In related news, insider Anil P. Ranganath sold 686 shares of the business's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $139.80, for a total value of $95,902.80. Following the sale, the insider now directly owns 13,955 shares in the company, valued at approximately $1,950,909. The trade was a 4.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Edward M. Basile sold 6,000 shares of the stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $115.63, for a total transaction of $693,780.00. Following the transaction, the director now owns 732 shares of the company's stock, valued at $84,641.16. This represents a 89.13% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 12,418 shares of company stock worth $1,512,613. Insiders own 7.00% of the company's stock.

Institutional Investors Weigh In On TransMedics Group

Institutional investors have recently made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of TransMedics Group by 244.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company's stock valued at $209,448,000 after purchasing an additional 2,209,996 shares in the last quarter. Braidwell LP bought a new position in TransMedics Group in the 4th quarter worth about $57,493,000. Norges Bank purchased a new position in TransMedics Group during the 4th quarter valued at about $22,861,000. Mackenzie Financial Corp increased its position in shares of TransMedics Group by 73.0% during the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company's stock valued at $51,635,000 after buying an additional 349,403 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of TransMedics Group by 1,565.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company's stock valued at $16,820,000 after buying an additional 253,624 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.